Oral Screening and Lesion Identification Systems
Customize your policy alerts
Sign up for Aetna Policy 0760 alerts
Get alerted when Policy 0760 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for oral screening and lesion identification systems and related adjunctive tests for early detection of oral cancer and premalignant lesions; applies to clinical use by providers performing oral screening and diagnostic adjuncts.
No material clinical or coverage changes in this revision.
Coverage Criteria and Evidence Summary
Experimental and Investigational
The following procedures are considered experimental and investigational because the effectiveness has not been established:
Listed verbatim as experimental/investigational in policy
Coverage considerations and clinical role
Coverage and clinical use considerations based on evidence presented
Supported by multiple systematic reviews and guidelines
Cochrane review, USPSTF, ADA and recent systematic reviews cited
Examples: margin assessment, high-risk cohorts; evidence limited and heterogeneous
Adjunctive imaging — evidence summary
Findings from systematic reviews and studies summarized in this section:
Summary of Lima et al, Dos Santos et al, Mendonca et al, GOCCLES and others; highlights performance ranges and need for validation
The policy lists multiple adjunctive technologies and biomarker assays that are considered experimental and investigational because their clinical effectiveness for early detection or diagnosis of oral cancer has not been established. Examples explicitly named include EBV antibody testing, oral HPV testing (e.g., OraRisk), numerous salivary biomarkers and hypermethylated DNA markers, tumor-derived exosomal biomarkers, and a range of device- and imaging-based aids (eg, chemiluminescence, confocal laser endomicroscopy, diffuse reflectance and fluorescence spectroscopy, narrow band imaging, optical fluorescence imaging including 5‑ALA induced PpIX and autofluorescence, GOCCLES, and commercial oral lesion identification systems such as ViziLite-Blue and VELscope). These listed technologies are therefore not supported for coverage under this policy.
Systematic reviews and guideline statements indicate that no evaluated imaging-based adjunct can substitute for a tissue diagnosis by biopsy and histopathology. A 2022 systematic review found inconsistent results across studies, high risk of bias, and concluded that none of the evaluated imaging methods could replace oral biopsy. Earlier reviews and guidance similarly note insufficient evidence to support routine population screening with adjunctive devices and recommend that these tools be used only as supplements to a comprehensive clinical oral examination (COE).
Screening for oral HPV infection is not recommended by major medical and dental organizations, and no FDA‑approved screening test for oral HPV infection currently exists. Although detection of oral HPV is an area of active research, available guidance does not support routine screening of asymptomatic populations for oral HPV.
Adjunctive tests such as vital staining, brush cytology and light‑based detection have not demonstrated sufficient quality of evidence to replace scalpel biopsy. Meta-analyses show variable accuracy across methods and overall study quality is poor; therefore, these adjunctive modalities cannot supplant histologic assessment as the definitive diagnostic standard.
Optical fluorescence, cytology and biomarker assays are discussed in the literature as potential adjuncts, but current evidence does not support their use as replacements for surgical biopsy and histopathological evaluation. Even when adjuncts provide immediate or less invasive results, confirmatory biopsy remains necessary to establish diagnosis and guide management.
Many salivary techniques and candidate biomarkers lack clinical validation, standardization, and robust prospective evidence. Studies frequently used research‑use‑only ELISA reagents, had heterogeneous methods of saliva collection and assay, small sample sizes, and variable reporting of diagnostic metrics. These limitations mean numerous salivary assays and other biomarkers remain unvalidated for routine clinical use.
Across imaging and probe-based adjuncts, authors consistently conclude that these techniques are unable to replace histopathological examination for definitive diagnosis. While some modalities (eg, certain fluorescent probes or spectroscopic methods) may show promising sensitivity or specificity in select studies, methodological heterogeneity, small cohorts, and lack of prospective outcome data preclude substituting imaging-based findings for biopsy and histology.
Adjunctive imaging devices should be considered aids to, not substitutes for, a comprehensive oral examination and targeted tissue biopsy. Guideline and systematic review conclusions emphasize that clinical decision-making should rely on COE and confirmatory histopathology; using adjunctive imaging as a standalone substitute for biopsy is unsupported by the evidence.
Computer‑aided cytology, liquid‑based cytology, and other adjunctive technologies have not demonstrated sufficient, consistent evidence to be recommended as replacements for scalpel biopsy. Systematic reviews identify oral cytology as having potential diagnostic value but do not endorse any adjunctive technique as a definitive alternative to histopathology.
The evidence does not support use of autofluorescence devices or fluorescent probes as standalone replacements for biopsy and histopathology to establish malignancy. Systematic reviews report variable performance metrics, lack of standardized fluorescence measurement thresholds, and frequent methodological limitations that preclude recommending these modalities as definitive diagnostic tests.
Coding and Billing
| 40899 | Unlisted procedure, vestibule of mouth |
| 41599 | Unlisted procedure, tongue, floor of mouth |
| 41899 | Unlisted procedure, dentoalveolar structures |
| 82397 | Chemiluminescent assay |
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44) |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed |
| D0431 | Adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including premalignant and malignant lesions, not to include cytology or biopsy procedures |
| G0476 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types for cervical cancer screening, must be performed in addition to pap test |
| A69.0 | Chancroid (example code listed in ICD-10 not covered list context) |
| K00.0-K14.9 | Disease of oral cavity, salivary glands, and jaws |
| C00.0-C10.9 | Malignant neoplasm of lip and oral cavity |
| D00.00-D00.08 | Carcinoma in situ of lip, oral cavity, and pharynx |
| D37.01-D37.02, D37.04-D37.09 | Neoplasm of uncertain behavior of lip, oral cavity, and pharynx |
| Z12.81 | Encounter for screening for malignant neoplasms of oral cavity |
| 86663-86665 | Antibody; Epstein-Barr (EB) virus |
Provider Responsibilities, Documentation, and Authorization
Coding and coverage identification
Coding and coverage identification — Codes associated with listed adjunctive tests and unlisted oral procedures are identified in this policy. Providers should bill the applicable CPT/HCPCS/ICD-10 codes noted in the policy; services for technologies or indications described as experimental/investigational or not supported by the policy may be denied.
- Relevant CPT/HCPCS examples: 40899, 41599, 41899 (unlisted oral procedures); 82397 (chemiluminescent assay); 87623-87625 (HPV NAATs); HCPCS D0431 (adjunctive pre-diagnostic test); G0476.
- ICD-10 examples noted as not covered for screening indications: Z12.81; C00.0-C10.9; D00.00-D00.08; D37.01-D37.09; K00.0-K14.9.
Denial risk for experimental/investigational technologies
Denial risk for experimental/investigational technologies — Use of procedures or assays described as experimental, investigational, pre-market, research-use-only, or lacking sufficient clinical validation may result in claim denial. Confirm plan-specific coverage before ordering or billing.
- Examples include Straticyte™ (pre-market), many salivary biomarker assays using RUO ELISA kits, novel microRNA or hypermethylated DNA panels, and certain optical/fluorescent probes without demonstrated clinical utility.
- Providers should verify medical necessity and local plan criteria; absence of stated coverage in the Clinical Policy Bulletin does not guarantee payment.
Clinical validation required
Clinical validation required — Many salivary assays, biomarker tests, and novel adjunctive technologies lack standardized collection, analytic validation, and robust prospective clinical validation. Such tests should not be used as replacements for histopathology and may be considered investigational until validated.
- Salivary cytokine and hypermethylated DNA studies show heterogeneity and use RUO reagents; standardization of saliva collection and assay platforms is needed.
- Stratified, multi-center prospective data demonstrating diagnostic accuracy and clinical utility are required before routine clinical adoption.
Plan-level prior authorization
Plan-level prior authorization — This Clinical Policy Bulletin provides guidance but does not itself establish prior authorization. Providers must follow plan-specific prior authorization requirements and check benefit documents or prior authorization portals before performing adjunctive tests or novel assays.
- Policy bulletin content does not replace plan administrative rules; contact the member's plan for authorization requirements.
- Failure to obtain required prior authorization may lead to claim denial or member liability.
Prior authorization
Prior authorization — No universal prior authorization is specified in this section; however, some tests or procedures (particularly novel assays, unlisted procedures, or experimental technologies) may require prior authorization under the member’s plan.
Insufficient evidence that routine screening reduces mortality
Insufficient evidence that routine screening reduces mortality — Systematic reviews and USPSTF guidance indicate insufficient evidence to recommend routine population screening for oral cancer using adjunctive devices or tests; routine screening outside established guidelines risks unsupported care.
- Professional bodies do not recommend routine oral HPV screening; no FDA-approved oral HPV screening tests exist.
- Routine use of adjunctive devices without appropriate clinical indications may not improve outcomes and can risk denial.
Adjunctive tests are not definitive
Adjunctive tests are not definitive — Adjunctive devices and tests (autofluorescence, chemiluminescence, toluidine blue, brush cytology, optical filters, salivary biomarkers) are aids to clinical assessment and are not replacements for scalpel biopsy and histopathologic diagnosis.
- None of the evaluated adjunctive methods can substitute for surgical biopsy and histological assessment; oral cytology shows promise but is not definitive.
- Adjunctive findings should be used to guide clinical judgment and decisions about referral and biopsy.
Adjunctive tools are not a substitute; devices are aids
Adjunctive tools are not a substitute; adjunctive devices are aids — Use adjunctive devices only in conjunction with a comprehensive clinical oral examination (COE). They may assist in lesion identification or targeting biopsy sites but do not replace COE, histopathology, or clinical judgment.
- When using devices like VELscope, ViziLite, or GOCCLES, perform and document a full COE and use device findings to inform, not replace, biopsy decisions.
- Positive adjunctive findings should prompt referral to experienced providers or biopsy when clinically indicated.
Imaging adjuncts do not replace biopsy
Imaging adjuncts do not replace biopsy — Non-invasive imaging modalities (autofluorescence, fluorescent probes, optical filters) can aid detection and surveillance but cannot replace histopathologic confirmation.
- Document that imaging was used to assist selection of biopsy site or surveillance; ensure biopsy and histology remain the diagnostic standard.
- Imaging may improve lesion conspicuity or help target biopsies in OPMD but is not diagnostic alone.
Clinical examination findings and rationale
Clinical examination findings and rationale — When adjunctive tests are used, document the comprehensive oral examination findings, risk factors, and the clinical rationale for selecting biopsy sites or surveillance rather than immediate biopsy.
- Document duration of lesion (any abnormality >2 weeks should be reevaluated and considered for biopsy), size, appearance, anatomic location, patient risk factors (tobacco, alcohol, immunosuppression), and device findings.
- If choosing surveillance instead of biopsy, record the rationale, follow-up interval, and criteria for escalation or biopsy.
Any abnormality in the oral cavity that persists >2 weeks
Any abnormality in the oral cavity that persists >2 weeks — Lesions lasting longer than 2 weeks should be reevaluated and considered for biopsy; adjunctive test results do not obviate this recommendation.
- Record follow-up plans and outcomes; persistent lesions, VELscope-positive areas that do not resolve within 2 weeks, or lesions with concerning features warrant further assessment and usually biopsy.
Assay and collection documentation
Assay and collection documentation — For salivary or other biomarker testing, document the assay platform, specimen collection method, reagent status (e.g., Research Use Only), and analytic validation status in the medical record.
- Standardize and record saliva collection protocols, storage conditions, and assay kit lot/brand when available.
- Note if assays use RUO reagents or lack clinical regulatory approval; include these details when submitting claims or prior authorization requests.
Documentation when using adjunctive imaging
Documentation when using adjunctive imaging — When autofluorescence, chemiluminescence, toluidine blue, or other imaging adjuncts are used, document the COE findings, device observations, targeted biopsy site selection rationale, and subsequent histopathology results.
- Include device type, settings or protocol used (if available), and whether software quantification was applied.
- Record referral actions, biopsy dates, and histologic outcomes to support medical necessity and appropriate follow-up.
Background and Context
Head and neck cancers account for roughly 5% of tumors, with about half arising in the oral cavity; early detection may reduce morbidity and mortality. Multiple adjunctive detection technologies have been evaluated to improve early identification of oral premalignant and malignant lesions, but current evidence is inconsistent and none of the adjunctive methods listed have sufficient validation to replace standard diagnostic pathways centered on clinical examination and biopsy.
Definitions and Device Descriptions
Policy Revision History
Policy became effective.
Policy was last reviewed.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.